CN111655680B - 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 - Google Patents

用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 Download PDF

Info

Publication number
CN111655680B
CN111655680B CN201880072464.XA CN201880072464A CN111655680B CN 111655680 B CN111655680 B CN 111655680B CN 201880072464 A CN201880072464 A CN 201880072464A CN 111655680 B CN111655680 B CN 111655680B
Authority
CN
China
Prior art keywords
azabicyclo
cyclopropyl
heptan
dichlorophenyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072464.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111655680A (zh
Inventor
J·晁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardelyx Inc
Original Assignee
Ardelyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardelyx Inc filed Critical Ardelyx Inc
Publication of CN111655680A publication Critical patent/CN111655680A/zh
Application granted granted Critical
Publication of CN111655680B publication Critical patent/CN111655680B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880072464.XA 2017-09-14 2018-09-14 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 Active CN111655680B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558858P 2017-09-14 2017-09-14
US62/558,858 2017-09-14
PCT/US2018/051122 WO2019055808A1 (en) 2017-09-14 2018-09-14 HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS

Publications (2)

Publication Number Publication Date
CN111655680A CN111655680A (zh) 2020-09-11
CN111655680B true CN111655680B (zh) 2024-03-05

Family

ID=63714148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072464.XA Active CN111655680B (zh) 2017-09-14 2018-09-14 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂

Country Status (6)

Country Link
US (1) US11753410B2 (https=)
EP (1) EP3681881B1 (https=)
JP (2) JP7271513B2 (https=)
CN (1) CN111655680B (https=)
MA (1) MA50242A (https=)
WO (1) WO2019055808A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548974A (zh) * 2009-08-19 2012-07-04 菲尼克斯药品股份公司 新型fxr(nr1h4)结合和活性调节化合物
CN103443099A (zh) * 2010-12-20 2013-12-11 Irm责任有限公司 调节fxr的组合物和方法
WO2016096115A1 (en) * 2014-12-17 2016-06-23 Gilead Sciences, Inc. Hydroxy containing fxr (nr1h4) modulating compounds
CN107106555A (zh) * 2014-12-18 2017-08-29 诺华股份有限公司 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228288B (it) 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
JP2014533258A (ja) 2011-11-15 2014-12-11 ゼンション・リミテッドＸｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
KR102400183B1 (ko) 2017-07-06 2022-05-18 수안주 바이오파마슈티컬 컴퍼니 리미티드 Fxr 작용제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548974A (zh) * 2009-08-19 2012-07-04 菲尼克斯药品股份公司 新型fxr(nr1h4)结合和活性调节化合物
CN103443099A (zh) * 2010-12-20 2013-12-11 Irm责任有限公司 调节fxr的组合物和方法
WO2016096115A1 (en) * 2014-12-17 2016-06-23 Gilead Sciences, Inc. Hydroxy containing fxr (nr1h4) modulating compounds
CN107106555A (zh) * 2014-12-18 2017-08-29 诺华股份有限公司 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用

Also Published As

Publication number Publication date
US11753410B2 (en) 2023-09-12
CN111655680A (zh) 2020-09-11
US20210380585A1 (en) 2021-12-09
EP3681881A1 (en) 2020-07-22
JP2020534275A (ja) 2020-11-26
EP3681881B1 (en) 2022-11-02
WO2019055808A1 (en) 2019-03-21
JP2023065577A (ja) 2023-05-12
MA50242A (fr) 2020-07-22
JP7271513B2 (ja) 2023-05-11

Similar Documents

Publication Publication Date Title
US11718619B2 (en) Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN106946867B (zh) Fxr受体调节剂及其制备方法和用途
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
CN110431134A (zh) 作为变构shp2抑制剂的吡啶化合物
CN111601799A (zh) 作为Il-17调节剂的稠合咪唑衍生物
CN110167935A (zh) 作为αV整合素抑制剂的3-经取代的丙酸
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
CN111295382A (zh) 作为法尼酯x受体调节剂的桥联双环化合物
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2008016131A1 (en) Fused heterocyclic compound
WO2019120088A1 (zh) 异噁唑衍生物及其制备方法和用途
CN104619709A (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN111511731A (zh) 作为法尼醇x受体调节剂的烯烃化合物
JP2023065577A (ja) 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
CN111278817A (zh) 作为法尼醇x受体调节剂的多环化合物
CN115427035A (zh) Enl/af9 yeats抑制剂
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
JP2024510434A (ja) Ｂｃｌ－２阻害剤として（（３－ニトロフェニル）スルホニル）アセトアミドを有する化合物
CN110191884A (zh) 取代的6-(1h-吡唑-1-基)嘧啶-4-胺衍生物及其用途
WO2024140638A1 (zh) 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用
TW202545534A (zh) Ｂｃｌ－２抑制劑
CN118103352A (zh) Kif18a的螺吲哚啉抑制剂
TWI922778B (zh) Ｂｃｌ-２抑制劑
CN118451070A (zh) Bcl-2抑制剂
HK40109522A (zh) 具有nrf2活化作用的含氮杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant